Barclays Maintains Overweight on Axogen, Lowers Price Target to $50
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and lowers the price target from $55 to $50.
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and lowers the price target from $55 to $50.